(Q53985559)

23 May 2018

title

Use of salivary caffeine tests to assess the inducer effect of a drug on hepatic metabolism. (English)

1 reference

23 May 2018

author name string

J Soto

series ordinal

1

1 reference

23 May 2018

J A Sacristan

series ordinal

2

1 reference

23 May 2018

M J Alsar

series ordinal

3

1 reference

23 May 2018

language of work or name

English

0 references

publication date

1 July 1996

1 reference

23 May 2018

Annals of Pharmacotherapy

published in

1 reference

23 May 2018

volume

30

1 reference

23 May 2018

issue

7-8

1 reference

23 May 2018

page(s)

736-739

1 reference

23 May 2018

Clinical Implications of Enzyme Induction and Enzyme Inhibition

cites work

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000705

Antipyrine as a model drug to study hepatic drug-metabolizing capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000705

Assessment of the drug metabolism capacity of the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000705

Caffeine: a model compound for measuring liver function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000705

The use of caffeine for enzyme assays: a critical appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000705

The absolute bioavailability of caffeine in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000705

Plasma and salivary pharmacokinetics of caffeine in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000705

Comparison of the urinary metabolite profile of caffeine in young and elderly males

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000705

Urinary metabolites of caffeine in pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000705

Pharmacokinetic drug interactions with rifampicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000705

Measurement of urinary 6-?-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000705

Interaction of sodium warfarin and rifampin. Studies in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000705

Enzyme induction and beta-adrenergic receptor blocking drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000705

Induction of polymorphic 4'-hydroxylation of S-mephenytoin by rifampicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000705

Bioavailability--a problem in equivalence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000705

The human hepatic cytochromes P450 involved in drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000705

10.1177/106002809603000705

21 January 2018

Identifiers

DOI

1 reference

23 May 2018

1 reference

23 May 2018